Phoenix Children’s Joins First Controlled Clinical Trial of Genetic Therapy for Dravet Syndrome
The first controlled phase 3 trial of a genetic therapy for Dravet syndrome is now underway – with Phoenix Children's as one of 28 sites nationwide.
Clinical Scorecard: Phoenix Children’s Joins First Controlled Clinical Trial of Genetic Therapy for Dravet Syndrome
At a Glance
| Category | Detail |
|---|
| Condition | Dravet Syndrome |
| Key Mechanisms | Pathogenic variants in the SCN1A gene affecting Nav1.1 voltage-gated sodium channel function. |
| Target Population | Pediatric patients with Dravet syndrome. |
| Care Setting | Clinical trial setting for genetic therapy. |
Key Highlights
- EMPEROR is the first controlled clinical trial for zorevunersen, a genetic therapy for Dravet syndrome.
- The therapy uses antisense oligonucleotides to modulate gene expression rather than traditional gene replacement.
- Clinical manifestations include pharmacoresistant seizures and developmental delay.
- The study aims to enhance seizure control and improve neurocognitive skills.
- Participants are closely monitored for safety and early clinical impact.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of Dravet syndrome typically involves genetic testing for SCN1A variants.
Management
- Focus on sustained seizure control and addressing developmental delays.
Monitoring & Follow-up
- Participants in the trial are monitored for safety, tolerability, and clinical impact.
Risks
- Increased risk of premature mortality, including sudden unexpected death in epilepsy (SUDEP).
Patient & Prescribing Data
Children diagnosed with Dravet syndrome.
Investigational therapy aims to upregulate expression from the functional SCN1A allele.
Clinical Best Practices
- Utilize genetic testing for accurate diagnosis of Dravet syndrome.
- Consider enrollment in clinical trials for access to emerging therapies.
Related Resources & Content
